Home/ Supplements/ Nac/ Aftermath

Aftermath

product on market Capsule Redcon1 Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 40% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

This profile includes ingredients like Mucuna pruriens and N-Acetyl Cysteine, which are studied for dopamine support and antioxidant activity. Evidence for the included anabolic compounds, such as Laxogenine and Androst-3,5-diene-7,17-dione, is generally limited in human clinical trials. Overall, the evidence coverage for this specific combination of ingredients is very low.

AI-generated summary based on research evidence. Not medical advice.

Label

Product Label

Label for Aftermath
Open Full PDF View on NIH DSLD →
Details

Label Data

2 Capsule(s)
Serving Size
30
Servings
Other Combinations
Product Type
40%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Mucuna pruriens
500 mg
Market median: 600.0mg (7 products) 39 studies (A:2, B:13)
100 mg
Market median: 100.0mg (283 products) 144 studies (A:1, B:64)
Androst-3,5-diene-7,17-dione
25 mg
Alpha Hydroxy Laxogenine
25 mg

Other Ingredients

Gelatin Magnesium Stearate Rice Flour
Claims

Label Claims — Verification

Unverified No Claim
Info

Product Information

Additional Information

PC7 Restore the order

Metadata

Product Details

DSLD Entry Date2020-01-25
Product TypeOther Combinations
FormCapsule
BrandRedcon1
DSLD ID172173
Data Updated2026-04-11
Research

Research Evidence

41
Research Sources
51
Avg Quality
19
Rct
13
Meta Analysis
9
Clinical Trial
B N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication
Meta Analysis The Cochrane database of systematic reviews 2019 PubMed DOI
B Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial
Rct Nature communications 2024 PubMed DOI
B N-acetylcysteine for non-paracetamol (acetaminophen)-related acute liver failure
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
B Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis
Meta Analysis European respiratory review : an official journal of the European Respiratory Society 2015 PubMed DOI
B A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo
Rct BMC medicine 2019 PubMed DOI
B Efficacy of N-acetylcysteine for patients with depression: An updated systematic review and meta-analysis
Meta Analysis General hospital psychiatry 2024 PubMed DOI
B Cysteine, cystine or N-acetylcysteine supplementation in parenterally fed neonates
Meta Analysis The Cochrane database of systematic reviews 2006 PubMed
B N-acetylcysteine as an adjunctive treatment for bipolar depression: A systematic review and meta-analysis of randomized controlled trials
Meta Analysis Bipolar disorders 2021 PubMed DOI
B N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials
Meta Analysis Psychopharmacology 2020 PubMed DOI
B N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses
Meta Analysis Archivos de bronconeumologia 2024 PubMed DOI
View all evidence for Nac →
Compare

Similar Products

View all Nac products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.